and over 400 top hospitals in India such as AIIMS , Manipal , Apollo , Breach Candy and Fortis , among others .
Founded by Leo Mavely in 2008 , Axio Biosolutions has spent close to a decade developing its line of proprietary products for the $ 12 billion + hemostat and advanced wound care market . This large perennial healthcare market has seen limited innovation , with developed and emerging markets continuing to use decades-old products which provide sub-optimal outcomes for patients and healthcare systems . Clinical studies have shown that Axio ’ s novel biomaterial-based technology platform delivers improved patient outcomes and cost efficiency , compared to other products in the market .
Key Milestones
Axio Biosolutions is now one of the largest chitosan medical products manufacturer globally and has a stateof-the-art manufacturing facility at Ahmedabad , India which is GMP , ISO 13485 certified and registered with USFDA .
With its deep R & D expertise , Axio also works closely with Brigham ’ s , Harvard Medical School . It has raised over $ 20 million till date and plans to build out its commercial presence in the US and EU , as well as strengthen its India operations . The company is well
positioned to grow in developed markets on the back of its intellectual property , regulatory approvals and clinical data .
In June 2021 , Axio received FDA 510 ( k ) clearance of its hemostatic product , Axiostat Patch that helps control moderate to severe bleeding in vascular procedures , surgical debridement sites , puncture sites and more . It has also got EU CE Mark to market Maxiocel for use in advanced wound care settings .
In March 2021 , the company expanded into the veterinary wound management space with the launch of SureKlot range of products . This advanced wound care range offers India ’ s first complete veterinary wound management solution to help control bleeding and support quick wound recovery in animals .
BIOVOICENEWS . COM 31